SEOUL, South Korea, May 3, 2019 /PRNewswire/ -- Samsung BioLogics (CEO: Tae Han Kim) and GI Innovation (CEO: Soo Yeon Nam) signed a Contract Development Organization (CDO) contract for immunochemotherapy at Samsung BioLogics headquarters on Thursday. GI Innovation signed this second...
from PR Newswire: https://prn.to/2GYkBjB
No comments:
Post a Comment